marketing wars over the new sleeping pills

September 2005

You'll see marketing wars over the new sleeping pills... Lunesta, Rozerem, Ambien CR, and then indiplon next year.

Lunesta (eszopiclone) is making a big splash now to get a head start. It's the first one not limited to short-term use... but some patients complain about a bitter aftertaste.

Rozerem (ro-ZER-um) will be out this month. It's the first in a new class...melatonin receptor agonists.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

marketing wars over the new sleeping pills
Women's Health Ortho Evra contraceptive patch and reports of deaths due to blood clots
Women's Health which drugs decrease efficacy of oral contraceptives (OCs)
Infectious Diseases CDC just released new guidelines for the 2005-2006 flu season
Diabetes two new investigational drugs for diabetes
a new inhaled corticosteroid called Asmanex
appropriate use of long-acting inhaled beta-agonists for asthma
alternatives to pseudoephedrine
Cholesterol There's confusion about all the different formulations of fenofibrate
Supplements how ginkgo interacts with other drugs
Supplements A new study is raising the question of whether echinacea is useful for the common cold
Dermatology iPledge, an even stricter risk management program for isotretinoin (Accutane, etc)
Pediatrics whether autism is caused by thimerosal in vaccines
Patient Privacy/HIPAA what HIPAA allows when discussing drug therapy
Practice higher risk of hypertension in women taking chronic NSAIDs or acetaminophen

marketing wars over the new sleeping pills

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents